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Abstract: (-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial ago-
nistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have sug-
gested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic con-
ditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of 
Parkinson’s disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxida-
tive mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal mod-
els. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
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1. INTRODUCTION 
  (-)-Stepholidine (SPD), extracted from the Chinese medicinal 
plant Stephania intermedia Lo (Fig. 1), belongs to an alkaloid of 
tetrahydroprotoberberines (THPBs). Initially, SPD was reported to 
decrease blood pressure without exerting any adverse effect on the 
heart [75, 84], and exhibited analgesia and sedative effects on the 
central nervous system (CNS) [6, 75]. Thereafter, the most impor-
tant findings, from behavioral, electrophysiological, biochemical, 
immunohistochemical and pharmacological studies, have revealed 
that SPD is a dopamine (DA) D1 receptor partial agonist and D2 
receptor antagonist [10, 11, 20, 28, 34, 37, 60, 62, 66, 82, 83, 87]. 
This unique neuropharmacological feature appears to have thera-
peutic potential because based on the concept of schizophrenia 
pathogenesis, an imbalance of brain DA function arises from dys-
function of D1 receptors in the medial prefrontal cortex (mPFC) 
and hyperactivity of D2 receptors in lower structures of cortex, such 
as the ventral tegmental area (VTA) and nucleus accumbens (NAc). 
The hypothesis of DA receptor imbalance has resulted in the devel-
opment of antipsychotic medicine. SPD is a novel, natural com-
pound, and may serve as a potential candidate for the treatment of 
schizophrenia and/or PD. This review focuses on the recent ad-
vances of SPD neuropharmacology. 
2. DAERGIC PATHWAYS AND RECEPTORS IN THE CNS 
  The DAergic system in the CNS plays important roles in the 
control of cognitive, motivational, motor and endocrine functions. 
DA exerts its pharmacological effects via specific DAergic recep-
tors, which are particularly expressed in the nigrostriatal and meso-
corticolimbic pathways.  
  The nigrostriatal pathway, which is comprised of DA-synthe-
sizing neurons of the substantia nigra pars compacta (SNc) that 
project to the striatum, contains nearly 80% of all the DA in the 
CNS. This pathway is crucial for motor coordination, and the de-
generation or dysfunction of this pathway results in the characteris-
tics of Parkinson’s disease (PD). The mesocorticolimbic pathway, 
which arises in the VTA and projects to the PFC and limbic areas, 
such as the NAc and the olfactory tubercle, is involved in regulating 
motivational behavior, learning, memory and cognition. The degen-
eration or dysfunction of this DAergic pathway is implicated in the 
development of schizophrenia. Therefore, this pathway may be the 
target of antipsychotics.  
  Recently, five subtypes of DAergic receptors, which belong to 
the family of seven-transmembrane heterotrimeric G-protein cou-
pled receptors, have been cloned and identified. Two different cate- 
*Address correspondence to this author at Neurophysiology Laboratory, 
Division of Neurology, Barrow Neurological Institute, 350 West Thomas 
Road, Phoenix, AZ 85013-4496, USA; Tel: (602) 406-6376; Fax: (602) 
406-7172; E-mail: Jie.Wu@chw.edu 
gories of DAergic receptors, termed D1-like (D1 and D5) and D2-
like (D2-D4), have been identified on the basis of DNA sequence 
similarities [61]. D1 receptors interact with Gs proteins to positively 
activate adenylyl cyclase, while D2 receptors act through Gi and Go
proteins to inhibit cAMP production. Thus, D1 and D2 receptors 
exert opposing effects and balance the two signaling pathways 
through the activation and inhibition of adenylyl cyclase activity.
Although D1 and D2 receptors belong to distinct subfamilies of DA 
receptors, several lines of evidence indicate there is an important 
functional linkage between these two subclasses of receptors. 
  Behavioral, biochemical and electrophysiological evidence has 
revealed synergism between D1 and D2 receptors [17, 21, 44, 65]. 
Calabresi et al. demonstrated that the abolished long-term depres-
sion (LTD) of synaptic transmission in the striatum after DA deple-
tion could be restored by exogenous DA or co-administration of 
specific D1 and D2 agonists, but not by application of either selec-
tive agonist alone [8]. Therefore, co-activation of D1 and D2 recep-
tors is required for LTD in the striatum. Using confocal micros-
copy, Aizman et al. observed that virtually all striatal neurons con-
tained both D1 and D2 receptors  [3]. Using both immunoprecipita-
tion and immunohistochemistry methods, Lee et al. demonstrated 
that D1 and D2 receptors are co-expressed and co-localized within 
striatal neurons and that these two receptors are part of the same 
heteromeric protein complex and a phospholipase C-mediated cal-
cium pathway that is only activated by both D1 and D2 receptor co-
activation [47]. These results demonstrate that D1 and D2 receptors 
are co-expressed in neurons of rat striatum, suggesting the possibil-
ity that there may be a direct D1-D2 receptor association. 
  Therefore, functional synergism between D1 and D2 receptors 
is necessary for maintaining some normal physiological functions, 
and once the functional linkage between the two receptors is bro-
ken, disorders, such as schizophrenia, may develop. 
3. DUAL EFFECTS OF SPD ON THE NIGROSTRIATAL 
PATHWAY  
  The DAergic system in the SNc, substantia nigra pars reticulata 
(SNr), neostriatum, globus pallidus, and subthalamic nucleus is 
known to play a pivotal role in the control and coordination of 
movement. In 1968, Ungerstedt developed a new technique for 
lesioning the nigrostriatal DA system by injecting 6-hydroxy-DA 
(6-OHDA) into the SN, which produced unilateral anterograde 
degeneration of the nigro-neostriatal DA system and constituted the 
first rat hemiparkinsonian model [67]. Using this model, subsequent 
study showed that rotational behavior could be induced by systemic 
administration of a DA agonist or amphetamine. It is well-known 
that amphetamine can increase DA turnover mainly by releasing 
DA from nerve terminals, thus seriously worsening the existing 
imbalance in DA neuronal activity between the lesioned and contra-
lateral sides. Collectively, these effects result in the animal rotating 
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  In the 1980s, Jin and colleagues started examining the pharma-
cological effects of SPD and its analogs using the 6-OHDA-induced 
PD rat model [60]. They first reported that SPD produced a signifi-
cant contralateral rotation, which was mimicked by the D1 agonist 
SKF38393 and blocked by the D1 antagonist SCH23390 [29, 31, 
34, 60], suggesting that SPD exhibits a D1 agonistic effect. Subse-
quent study showed that SPD exhibited a direct agonist effect on 
neurons in the nigrostriatum and SNr [82]. Moreover, in vitro radio-
ligand binding assay demonstrated that SPD was able to bind to the 
D1 receptor at two sites, a high-affinity site (Ki = 3.9 nM) and a 
low-affinity site (Ki= 126 nM), using calf striatal membrane prepa-
rations [16]. These results strongly suggest that SPD exerts an ago-
nistic effect on D1 receptors under 6-OHDA-induced lesioned con-
ditions.  
  In contrast, in control and reserpinized rats (rodents treated with 
reserpine at 1 mg/kg for 6 days to deplete endogenous DA), SPD 
exerts an antagonist effect on the D1 receptor. SPD reversed and/or 
significantly attenuated SNc DA cell firing induced by SKF38393 
or by the mixed DA receptor agonist apomorphine (APO) in reser-
pinized rats. This effect was similar to that produced by SCH23390 
[62, 64]. It has been shown that SPD only partially (51-53%) re-
verses the effects of SKF38393 but completely (100%) reverses the 
effects of SCH23390 [64]. Zou et al. demonstrated that SPD dis-
plays D1 agonistic effects at a low dose (0.5 or 1 mg/kg) but D1 
antagonistic effects at a high dose (4 or 10 mg/kg) when co-
administered with APO during behavioral experiments [90]. Fur-
thermore, binding experiments showed that SPD binds to the D1 
receptor with high affinity (Ki = 13 nM, [76]), but exhibits much 
lower affinity for other receptors [35, 84]. 
What is the mechanism by which SPD exhibits this controver-
sial effect on the D1 receptor? Although the exact reasons for this 
difference are still uncertain, it is clear that SPD shows D1 agonis-
tic action in the presence of SCH23390 and exhibits antagonistic 
effects in the presence of SKF38393, meaning that as a partial ago-
nist, SPD displays a large range of intrinsic activities at the same 
D1 receptors depending on different conditions. Another possible 
reason explaining this controversial effect is that the D1 receptor 
may exhibit different sensitivities under these two conditions. In the 
6-OHDA-induced lesioned model, a relatively large amount of 
endogenous DA is depleted, which consequently enhances D1 re-
ceptor sensitivity. However, in normal rats, D1 receptors are not 
sensitive enough to observe the agonistic effects of SPD [62, 90]. 
  In conclusion, SPD modulates D1 receptors depending on the 
receptor’s status. Under normal conditions, SPD works as a D1 
receptor antagonist, while in the 6-OHDA-induced PD model, SPD 
serves as a partial agonist.  
  In addition to modulating D1 receptor function, SPD also show 
the ability to bind to the D2 receptor. Although its affinity for the 
D2 receptor (Ki = 85 nM) is 4-7 times lower compared to the D1 
receptor (Ki = 13 nM) [76], SPD shows much lower or poor affinity 
for other receptors [35, 84]. It has been reported that SPD also 
modulates D2 receptor function. In normal rats, SPD antagonized 
APO-induced stereotypy [84], reduced the inhibitory effect of APO 
on the firing activity of nigral DA neurons and shifted the dose-
response curve to the right [29], increased striatal Levodopa (L-
dopa) and 3,4-dihydroxyphenylacetic acid accumulation induced by 
NSD1015 (a decarboxylase inhibitor) [26], and increased striatal 
DA release [30]. Moreover, SPD antagonized or reversed D2 recep-
tor-mediated inhibition of synaptosomal adenylate cyclase (AC), 
which can be isolated from rat striatum, by affecting regulation of 
Gi proteins on D2 receptor-coupled AC [28]. In reserpinized rats, 
SPD reversed N0437 (a D2 receptor agonist)-induced inhibition of 
DA cell firing in the SNc, suggesting that SPD acts as a D2 receptor 
antagonist [62]. In 6-OHDA-induced lesioned rats, unlike its D1 
receptor agonistic effect, SPD induced animal rotation towards the 
intact side by blocking D2 receptors [15, 34, 37, 86]. Therefore, 
SPD is a D2 antagonist.
4. DUAL EFFECTS OF SPD ON THE MESOCORTICOLIM-
BIC PATHWAY 
  SPD-induced dual D1 receptor agonistic and D2 receptor an-
tagonistic effects have also been demonstrated in mesocorticolimbic 
structures, including the mPFC, NAc, and VTA DAergic systems. 
An in vivo electrophysiological study in rats demonstrated that at a 
low dose (1-64 g/kg), SPD increased VTA DA cell firing and 
attenuated APO-induced inhibition of DA cell spontaneous firing, 
suggesting that SPD blocks D2 receptors located on VTA DA cells, 
thereby feed-back regulating spontaneous activity [63]. However, at 
a high dose (0.6-3.3 mg/kg), SPD continuously decreased the am-
plitude of spikes from spontaneously-firing cells until the majority 
(4/6) of VTA DA neurons became inactive. This manner of inhibi-
tion by SPD was reversed by APO and was different from inhibi-
tion resulting from APO-induced hyperpolarization. In addition, 
SPD was reported to produce a depolarization-induced inactivation 
(cessation of spontaneous firing due to excessive depolarization) of 
DA neurons in the VTA [37, 63]. 
 Additional  in vivo experiments using rats have demonstrated 
that intravenous (i.v.) administration of SPD (from 0.01 mg/kg to 2 
mg/kg, each dosage doubled every 2 minutes) produced two oppos-
ing effects on the spontaneous firing of NAc neurons. Since D2 
receptors on VTA DA neurons are 3-10-fold more sensitive to SPD 
than those in the NAc (which receives neuronal input from the 
VTA), a low dose (0.02-0.08 mg/kg) of SPD blocked D2 receptors 
on VTA DA neurons [87] and reduced DA release from nerve ter-
minals in the NAc [89]. Therefore, a low dose of SPD produces an 
inhibitory effect on the spontaneous firing of NAc neurons due to 
this disinhibitory effect. However, a high dose (0.08-2 mg/kg) of 
SPD produces a biphasic effect (decrease followed by increase) on 
the firing activity of NAc neurons [87], meaning inhibitory then 
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subsequently excitatory effects on the spontaneous firing of NAc 
neurons. The inhibitory effect is due to the previously mentioned 
disinhibitory effect via blockade of VTA D2 receptors. With pre-
treatment of spiperone (a D2 antagonist), only an excitatory effect 
is observed, but the excitatory effect is reversed by SCH23390, 
which suggests that SPD works as a D1 receptor agonist and in-
duces excitation [87]. The D1 agonistic effect of SPD on spontane-
ous firing, however, is not observed in the NAc using direct mi-
croiontophoresis [88], suggesting that the D1 agonistic effect of 
SPD (i.v.) on NAc DA neurons is probably mediated by some indi-
rect action in the mesocorticolimbic system. Actually, emerging 
evidence suggests that SPD-induced excitation is indirectly medi-
ated via the mPFC D1 receptor [37, 88, 89]. Furthermore, an im-
munohistochemical study confirmed that D1 receptors are located 
on mPFC pyramidal neurons, which project directly to the NAc 
with glutamate-mediated (excitatory) efferents [5]. Therefore, it is 
possible that SPD directly activates D1 receptors on mPFC gluta-
matergic neurons that project to the NAc, thus indirectly influenc-
ing neuronal activity in the NAc. Consequently, the biphasic effect 
in the NAc induced by SPD is likely mediated by its antagonistic 
action on D2 receptors in the VTA and its agonistic effect on D1 
receptors located in the PFC meso-accumbens DA system [87].  
5. EFFECTS OF SPD ON PERIPHERAL DA RECEPTORS 
AND CA
2+ CHANNELS AND ITS ANTIHYPERTENSIVE 
ACTION 
It is well-known that specific DA receptors are expressed in 
both the CNS and extracerebral structures. In particular, DA recep-
tors are present on vascular smooth muscle cells (vascular DA re-
ceptor) [79] and on postganglionic sympathethic nerve terminals 
(neuronal DA receptor) [32]. It has also been demonstrated that 
peripheral DA receptors are expressed in mammals at many sites, 
such as vascular smooth muscle, autonomic nerve endings in the 
cardiovascular system, autonomic ganglia, the kidneys, and so on 
[73]. Functionally, activation of the vascular DA receptor (D1 re-
ceptor) causes smooth muscle relaxation, whereas activation of the 
neuronal DA receptor (D2 receptor) reduces the response of the 
heart to nerve stimulation by depressing noradrenaline release [22, 
27, 45, 48]. Thus, peripheral DA receptors participate in the regula-
tion of peripheral vascular resistance, and in turn improve cardio-
vascular [33] and renal functions including vasodilatation, diuresis 
and natriuresis [12]. 
  Evidence suggests that hypertension results from overactivity of 
central DA neurons in spontaneously hypertensive rats (SHRs). The 
prevailing opinion is that D2-like receptor function is upregulated 
in SHRs [43, 51, 71]. In addition to the central DA receptor system, 
renal and adrenal DAergic dysfunction may also play roles in the 
pathophysiology of hypertension. In human hypertension, a reduced 
ability of DA to regulate sodium excretion (most likely a D1-like 
receptor mechanism is impaired) has been reported [4, 39, 40]. 
Differences in D1-like receptor regulation of diuresis, natriuresis, 
Na
+-K
+-ATPase activity, and rat renal protein kinase C isoform 
expression between normotensive and hypertensive rats suggest that 
renal D1-like receptor dysfunction may be the mechanism respon-
sible for generation of hypertensive rats [78]. Gordon et al. discov-
ered that aberrant DAergic regulation of aldosterone secretion me-
diated via DA D2-like receptors may also contribute to hyperten-
sion [23]. The absence of interactions between D1/D2 receptors has 
also been reported in the kidneys of SHRs, but not in normotensive 
rats [70]. In addition, it has been suggested that stimulation of D1- 
or D2-like DAergic receptors may constitute a therapeutic strategy 
for the treatment of hypertension [4]. 
  As mentioned above, SPD is a D1 receptor partial agonist and 
D2 receptor antagonist in the CNS, and studies have demonstrated 
that SPD also exerts dual effects on peripheral DA receptors. SPD 
(0.1-10M) shifts dose-response curves to the right and decreases 
the maximal response of both fenoldopam (a selective D1 agonist)-
induced and propyl-butyl-DA (a selective D2 agonist)-induced 
vasorelaxation, showing a non-competitive antagonistic action on 
both D1 and D2 receptors. In addition, SPD (0.1-100M) induces 
slight but dose-dependent vasorelaxation of renal and pulmonary 
arteries, thereby displaying D1 agonistic activity [81].  
  It is possible that SPD may be a promising antihypertensive 
agent due to its interaction with both central and peripheral DA 
receptors. Furthermore, the inhibitory effect of SPD on 1-adreno-
ceptor-mediated contractile responses evoked by nerve-released and 
exogenous noradrenaline in peripheral small- resistance arteries 
might contribute to its antihypertensive effect  [48].  
  In addition, SPD has been reported to inhibit Ca
2+ release and 
block Ca
2+ channels. Using aortic strip preparations, a low dose 
(0.3-100 M) of SPD inhibited norepinephrine (NE)-induced Ca
2+
release from intracellular stores [58] whereas a high dose (3-30 
mM) blocked voltage-dependent Ca
2+ channels [50, 52, 58]. SPD 
also inhibited the elevation of cytosolic free Ca
2+ induced by high 
extracellular Ca
2+ and NE [50]. However, the blocking effect on 
Ca
2+ channels by SPD was weaker than that of verapamil (a cal-
cium channel blocker) [77].  
  Collectively, SPD reverses the contraction of peripheral arteries 
in cerebral, mesenteric, renal and coronary regions, and results in a 
decrease of total peripheral resistance, thus leading to its antihyper-
tensive effects [59].  
6. NEUROPROTECTIVE EFFECTS OF SPD 
  Morphological and biochemical experiments have demonstrated 
that SPD possesses neuroprotective effects [66]. The possible phar-
macological mechanisms of SPD-induced neuroprotection are com-
plex. First, in a rat four-vessel occlusion model, SPD prevented 
ischemia-induced inhibition of calcium/calmodulin-dependent pro-
tein kinase II (CCDPKII) [66]. The preservation of activity of 
CCDPKII may be involved in the mechanism of neuronal protec-
tion against ischemia [69]. Second, SPD reduced lactate dehydro-
genase, an indicator of injury, from neurons following ischemia, 
suggesting that SPD protects neurons against hypoxia-induced in-
jury, which has been further confirmed by histological studies in 
striatal neurons [66]. Third, the neuroprotective effects of SPD may 
be related to its ability to scavenge hydroxyl free radicals. It was 
reported that SPD and its analogs (i.e., THPBs) decreased the con-
centration of malondialdehyde brain homogenate and scavenged 
OH
 [38]. Recently, Zhang et al. found that SPD increased levels 
of phospho-AKt, thus keeping neurons viable following exposure to 
H2O2 neurotoxicity. These results suggest that SPD can maintain 
cell survival following exposure to certain neurotoxins or serve as 
an antiapoptotic factor [80]. Finally, SPD increased the number of 
both microtubule-associated protein-2-immunoreactive cells and 
proliferated precursor cell spheres in cultured striatal precursor 
neurons pretreated with fibroblast growth factor-2. In addition, SPD 
also promoted the expression of tyrosine hydroxylase in these cells. 
These results suggest that SPD may regulate neuronal proliferation 
and promote neuronal differentiation of striatal-derived neural pre-
cursor cells [25].  
  Considering all of its effects, SPD may be utilized as a cytopro-
tective drug to attenuate ischemia-induced neuronal injury, thereby 
maintaining neuronal survival, and may even be used to promote 
neuronal regeneration. These properties of SPD suggest potential 
therapeutic applications for the treatment of neurodegeneration. 
7. POTENTIAL APPLICATIONS 
7.1. SPD for the Treatment of Schizophrenia 
  Schizophrenia is a chronic, devastating mental disorder. It is 
characterized by the presence of both negative and positive symp-
toms. Schizophrenia is the most serious of all psychiatric illnesses 
and affects about 1% of the world's population, but the etiology of 
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experimental studies, the cause of schizophrenia may involve an 
imbalance of cortical/subcortical DA systems. Specifically, hyper-
activity of D2 receptors in subcortical mesolimbic regions, such as 
the NAc, may produce the positive symptoms of schizophrenia, 
while hypofunction of D1 receptors in the mPFC is considered to be 
responsible for the negative symptoms and cognitive impairment [9, 
14, 55].  
  D1 and D2 receptors have important functional interactions (see 
section 2). However, these interactions were abnormal in over half 
of the postmortem striata from schizophrenic patients, suggesting 
an impaired functional linkage between D1 and D2 receptors in 
schizophrenic patients [57]. Therefore, the restoration of normal, 
functional linkage between D1 and D2 receptors may be an effec-
tive strategy for the treatment of schizophrenia.  
  Before atypical neuroleptics were discovered, clinical doses of 
the available antipsychotic drugs primarily blocked D2 receptors 
[13, 56], but unfortunately they were less effective at PFC D1 re-
ceptors. As a result, a large proportion of schizophrenic patients did 
not show adequate relief from their negative symptoms [1]. How-
ever, even with the development of atypical neuroleptics, most of 
them display only very small D1 agonistic effects on the PFC D1 
receptor. Therefore, there is an urgent need to develop an agent that 
exerts both D1 agonistic and D2 antagonistic effects, which should 
more effectively restore synergism between D1 and D2 receptors 
and alleviate both the negative and positive symptoms of schizo-
phrenia. SPD possesses these characteristics and may serve as a 
novel, promising agent for schizophrenia therapeutics. 
  Clinical trials are currently testing the potential use of SPD as 
an antipsychotic drug. Co-administration of SPD and typical antip-
sychotic drugs (e.g., phenothiazines or butyrophenones) could sig-
nificantly enhance the effectiveness of drug therapy for mental 
disorders. In addition, SPD alone has been shown to exhibit a sig-
nificant therapeutic effect. Furthermore, a double-blind comparative 
study demonstrated that SPD not only improved the positive symp-
toms of schizophrenia, but also significantly alleviated the negative 
symptoms compared to perphenazine, a common drug prescribed 
for schizophrenic patients [36, 37, 74]. Recently, experiments have 
also demonstrated that SPD exerts its antipsychotic-like effects in a 
schizophrenic animal model with few extrapyramidal side effects  
[18]. The promising therapeutic effects of SPD probably are the 
result of its dual D1 agonistic and D2 antagonistic effects, which 
can potentially reverse hyperactivity of D2 receptors in subcortical 
mesolimbic regions and restore normal function of D1 receptors in 
the mPFC, thus restoring normal, functional linkage between D1 
and D2 receptors.
7.2. SPD for the Treatment of PD 
  PD, after Alzheimer’s disease, is the second most common 
progressive neurodegenerative disorder in the United States, affect-
ing about one million people, with more than 50,000 new cases 
being diagnosed each year. Its prevalence in the U.S. population 
aged over 50-years old is above one percent, and likely exceeds five 
percent in individuals aged over 80-years old [72]. As a result, PD 
is a relatively frequent disorder that occurs in older populations. 
  The pathogenesis of PD typically is slow-paced but relentlessly 
progressive. Understanding of the etiopathogenesis of PD is still 
limited. According to current knowledge, PD develops as a conse-
quence of DAergic neuronal degeneration in the SNc. It appears 
that several factors (such as oxidative stress, glutamate toxicity, and 
genetics) contribute to this degenerative process [7, 42], but oxy-
gen-containing free radicals, especially OH
 may play a key role 
[2, 19, 42, 53]. Another important factor is that the unique bio-
chemical features of the SN, such as containing “a high content of 
oxidizable DA, neuromelanin, polyunsaturated fatty acids, and iron, 
and relatively low antioxidant complement with high metabolic 
rate” render the SN, particularly its zona compacta, vulnerable to 
oxidative damage [42]. As a result, the number of surviving DA 
neurons decreases to less than 20% in the nigrostriatum following 
the development of PD.  
  The most accepted therapeutic strategy for the treatment of PD 
is essentially DA replacement. L-dopa, the direct precursor of DA, 
in combination with carbidopa, remains the most effective drug 
combination. The majority of patients taking these drugs experience 
benefits initially, but drug effectiveness declines after 2-5 years, 
evidenced by the emergence of significant adverse effects associ-
ated with L-dopa. Long-term L-dopa therapy increases oxidative 
burden [42], thus worsening oxidative stress, neurodegeneration 
and the loss of DA neurons. Recently, it has been found that long-
term L-dopa therapy results in dyskinesia due to the over-
expression of D3 receptors in brain-selective nuclei [41]. Therefore, 
there is a considerable need for new drugs aimed at relieving the 
motor symptoms associated with PD by directly depressing D3 
receptor expression and protecting surviving DA neurons against, 
or slowing down the progression of, neuronal degeneration in the 
SN [24, 54]. 
  SPD may be potentially used as a novel therapeutic strategy for 
PD. As previously described, SPD not only protects striatal cells 
against transient cerebral ischemic injury [66], but also scavenges 
hydroxyl free radicals and maintains neuronal survival following 
exposure to H2O2 neurotoxicity [38, 80]. More importantly, SPD 
possesses D3 receptor antagonism, and it has been co-administered 
with L-dopa for the treatment of PD [46]. Also, SPD and THPB-18 
protect DA neurons against damage induced by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl-pyridinium (a 
selective DA neuron toxin) [49]. In addition, SPD may promote 
proliferation and differentiation of neuronal precursor cells [25]. 
Furthermore, preliminarily clinical trials have demonstrated that 
SPD, in combination with a low dose of bromocriptine, can allevi-
ate the symptoms of PD [49]. Thus, SPD may be able to exert 
symptomatic therapeutic effects and prevent further DA neuron 
degeneration in PD.  
  Animal experiments have demonstrated that SPD is well-
absorbed in the digestive tract, can be widely distributed in body 
tissues, and can easily penetrate the blood-brain barrier [85]. SPD 
may also be suitable for patients with PD and hypertension since it 
can decrease blood pressure. Taken collectively, SPD is a unique, 
promising novel drug that potentially can be used for the treatment 
of PD due to its ability to exert both symptomatic therapy and neu-
roprotection. 
8. CONCLUSION 
SPD has been shown to possess dual D1 agonistic and D2 an-
tagonistic effects in both the nigrostriatal and mesocorticolimbic 
DAergic pathways. Thus, SPD potentially reverses hyperactivity of 
subcortical D2 receptors and restores PFC dysfunctional D1 recep-
tors in patients with schizophrenia, which would result in the recov-
ery of functional linkage between D1 and D2 receptors. SPD not 
only treats the positive symptoms of schizophrenia, but also allevi-
ates the negative symptoms. In addition, SPD also potentially re-
lieves the motor symptoms of PD due to its D1 agonistic and D3 
antagonistic effects. Furthermore, SPD exhibits neuroprotective 
effects by scavenging hydroxyl free radicals, and consequently, 
results in the slowing down of neuronal degeneration in the SN of 
patients with PD. Considering its features, such as being well-
absorbed in the digestive tract, can be widely distributed in body 
tissues, and can easily penetrate the blood-brain barrie  [85], as well 
as its dual pharmacological effects on D1 and D2 receptors, SPD is 
a unique, novel and promising drug for the treatment of schizophre-
nia and/or PD. 
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ABBREVIATIONS 
SPD =  (-)-stepholidine 
PD =  Parkinson’s  disease 
SN =  Substantia  nigra 
SNc  =  Substantia nigra pars compacta 
SNr  =  Substantia nigra pars reticulata 
 DA  =  Dopamine 
THPBs =  Tetrahydroprotoberberines 
CNS  =  Central nervous system 
mPFC  =  Medial prefrontal cortex 
VTA =  Ventral  tegmental  area 
NAc =  Nucleus  accumbens 
6-OHDA = 6-hydroxy-DA 
APO =  Apomorphine 
L-dopa =  Levodopa 
AC =  Adenylate  cyclase 
i.v. =  Intravenous 
SHRs =  Spontaneously  hypertensive  rats 
NE =  Norepinephrine 
CCDPKII  =  Calcium/calmodulin-dependent protein kinase II 
AD =  Alzheimer’s  disease 
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